Nxera Pharma announced robust operational and financial results for Q1 2026, driven by new licensing agreements, including a deal with Santhera for Duchenne Muscular Dystrophy treatment in Asia-Pacific. The company achieved multiple R&D milestones, resulting in significant milestone payments and improved profitability, with net profit rising to JPY 1.79 billion from a prior loss. Strategic partnerships, including the acquisition of Centessa Pharmaceuticals by Eli Lilly, position Nxera for continued growth. Nxera expects 2026 to be a pivotal year for sustained growth and value creation for patients and shareholders.
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
Sanofi reported robust sales growth in Q1 2026, with Sarclisa sales rising 30.1% to $193.21 million and Dupixent sales increasing 30.8% to $4.85 billion. The company is expanding Sarclisa's reach with an on-body injector to compete in the multiple my...
Sanofi disclosed its total number of issued shares and voting rights as of May 31, 2026. The company has issued 1,214,099,027 shares, with 1,333,575,416 real voting rights excluding treasury shares, and a theoretical total of 1,349,603,933 voting rig...
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
